

ASX Announcement Confirmation of Compliance with

ASX Chapter 12

SYDNEY 12 OCTOBER 2023– Allegra Orthopaedics Limited (**Allegra**) (ASX: AMT) is pleased to advise that, in the opinion of the ASX, the current level of operations and the financial condition of Allegra is adequate to warrant continued listing and quotation of the Company's securities with the ASX.

This announcement follows the Company's announcement dated 2 May 2023 and the Entitlement Offer booklet dated 19 July 2023, which noted the Company's responsibilities to satisfy the ASX of compliance with ASX Chapter 12, following entry into the agreement for the sale of the Orthopaedic Division on 2 May 2023, else risk suspension and/or re-compliance with Chapters 1 and 2 of the ASX Listing Rules.

The ASX further advised that the ASX will continue to monitor the progress and future circumstances of AMT and it should be noted that under ASX Listing Rule 18.3, ASX may at any time vary or revoke its decision made.

This announcement has been authorised for release by the CEO of Allegra.

Contact details:

Robyn Slaughter Company Secretary T: +61 2 8072 1435

ABOUT ALLEGRA ORTHOPAEDICS:

We aim to help bring the freedom and happiness of pain-free movement to people's lives. We achieve this through providing the best possible solutions for patients, from world-wide industry leading orthopaedic products through to Australian innovations. Allegra's principal product, the Active Total Knee, has significantly improved the quality of life for many people and remains a focused product line. Allegra is also the exclusive distributor of Waldemar Link GmbH & Co. KG products in Australia. Link consists of a range of complex lower limb, hip and knee replacements, including oncology solutions. The Link products add to Allegra's well-developed range of products for distribution from international suppliers covering all specialties from foot and ankle to upper limb. The company is pleased to continue to build upon its extensive portfolio of patents. It has strong research relationships with universities, companies and surgeon inventors.